3649 results for «414»

Filter By

3649 results

Mitral valve disease: guidelines and beyond

21 Nov 2021 – From PCR London Valves 2021

In this session from PCR London Valves 2021 dedicated to the new guidelines relating to the management of mitral valve disease, discover how to apply them in your everyday clinical practice to the care of your patients through presentations, interviews, heart team discussions, a live case...

Mitral valve disease: guidelines and beyond

Mitral valve disease: state-of-the-art

21 Nov 2021 – From PCR London Valves 2021

Did you ever wonder what an expert surgeon can achieve today in mitral repair? Have you ever wondered when to treat an asymptomatic patient with severe mitral regurgitation? These are some of the questions this session from PCR London Valves 2021 will try to answer.

Mitral valve disease: state-of-the-art

Transcatheter mitral interventions: the future

21 Nov 2021 – From PCR London Valves 2021

What could be the future of transcatheter mitral valve intervention? Will it be repair or replacement? What are the current limitations? Find parts of the answers to these questions, and many others, in this session shot during the PCR LV 2021 Congress.

Transcatheter mitral interventions: the future

The impact of the first transcatheter heart valve on the lifetime management of patients with aortic stenosis

18 May 2022 – From EUROPCR 2022

This session from EuroPCR 2022 will help you understand how the first bioprosthetic aortic valve may affect long-term outcomes of patients with aortic stenosis. Learn how to optimise their lifetime management and how to refine procedural steps during TAVI.

The impact of the first transcatheter heart valve on the lifetime management of patients with aortic stenosis

Innvolution Healthcare reports one-year findings from the ALCHEMY study evaluating Eternia in 1000 patients at EuroPCR 2026

27 May 2026

Four-Year Outcomes from the EVOLUT Low Risk Trial

26 Oct 2023

Dejan Milasinovic provides his take on the EVOLUT Low Risk trial, presented by Michael I. Reardon at TCT Congress 2023. 4-year results reveal a continuing trend towards lower combined rates of all-cause mortality and disabling stroke with TAVI compared with surgical aortic valve replacement (SAVR)

Dejan Milasinovic

Author

Dejan Milasinovic
Four-Year Outcomes from the EVOLUT Low Risk Trial

5-year outcomes after transcatheter or surgical aortic valve replacement in low-risk patients with aortic stenosis (Evolut Low Risk)

01 Apr 2025

Yohei Ohno provides his takeaways from the results of the Evolut Low Risk trial which was presented by Michael J. Reardon during the ACC.25 in Chicago.

Yohei Ohno

Author

Yohei Ohno
5-year outcomes after transcatheter or surgical aortic valve replacement in low-risk patients with aortic stenosis (Evolut Low Risk)

Transcatheter vs surgical aortic valve replacement in aortic stenosis patients at low surgical risk: 3-year outcomes from the Evolut Low Risk trial

05 Mar 2023

Luigi Biasco provides his take on the clinical trial presented by John K. Forrest from Yale University School of Medicine, New Haven, Connecticut, USA during the 2023 ACC/WCC annual congress held in New Orleans, Louisiana.

Luigi Biasco

Author

Luigi Biasco
Transcatheter versus surgical aortic valve replacement in aortic stenosis patients at low surgical risk: 3-year outcomes from the Evolut low risk Trial

Cardiac biomarkers in patients with asymptomatic severe aortic stenosis: primary biomarker analysis from the EARLY TAVR Trial

01 Apr 2025

Elad Asher provides his take on the primary biomarker analysis from the EARLY TAVR Trial presented by Brian R. Lindman at ACC.25 in Chicago.

Elad Asher

Author

Elad Asher
Cardiac biomarkers in patients with asymptomatic severe aortic stenosis: Primary biomarker analysis from the EARLY TAVR Trial
Didn’t find what you were looking for?